Safety profile of belatacept in a real-life setting: disproportionality analysis of the WHO pharmacovigilance database
Abstract Background Belatacept is a co-stimulation blocker used in kidney transplant recipients to prevent allograft rejection. Unlike calcineurin inhibitors, belatacept is non-nephrotoxic and may carry a lower risk of cardiovascular and metabolic complications. However, the European Medicines Agenc...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
BMC
2025-08-01
|
| Sraith: | BMC Pharmacology and Toxicology |
| Ábhair: | |
| Rochtain ar líne: | https://doi.org/10.1186/s40360-025-00972-6 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|